Geode Capital Management LLC Sells 5,438 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Geode Capital Management LLC trimmed its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 0.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,617,137 shares of the company’s stock after selling 5,438 shares during the quarter. Geode Capital Management LLC owned about 1.66% of Poseida Therapeutics worth $4,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of PSTX. Marshall Wace LLP bought a new position in Poseida Therapeutics during the second quarter worth $31,000. Principal Financial Group Inc. bought a new position in Poseida Therapeutics in the second quarter worth approximately $35,000. Intech Investment Management LLC acquired a new stake in Poseida Therapeutics in the 3rd quarter valued at $46,000. Mackenzie Financial Corp bought a new stake in Poseida Therapeutics during the 2nd quarter valued at $51,000. Finally, SG Americas Securities LLC acquired a new position in Poseida Therapeutics during the third quarter worth $70,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

Insider Activity

In other news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total value of $283,800.00. Following the transaction, the chairman now owns 651,291 shares of the company’s stock, valued at approximately $6,161,212.86. This represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.90% of the stock is owned by company insiders.

Poseida Therapeutics Price Performance

Shares of NASDAQ PSTX opened at $9.52 on Monday. The stock has a fifty day moving average of $6.66 and a 200-day moving average of $4.25. Poseida Therapeutics, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $9.65. The stock has a market cap of $930.81 million, a PE ratio of -15.11 and a beta of 1.63. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20.

Analysts Set New Price Targets

PSTX has been the subject of several recent analyst reports. Piper Sandler lowered shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 target price for the company. in a research note on Monday, December 2nd. HC Wainwright restated a “neutral” rating and set a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.50.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.